Cambridge Cognition Holdings plc is a United Kingdom-based brain health software company, which is engaged in developing and marketing digital solutions to assess brain health, principally in the United Kingdom, the United States and Europe. The Company's operates through four market segments: Clinical Studies, Academic Research, Professional Healthcare, and Consumer Health & Wellness. Its products include CANTAB, Electronic Clinical Outcomes Assessment (eCOA), NeuroVocalix, Winterlight, Cognition Kit, Clinpal, eConsent, and AQUA. CANTAB Connect gives the control to manage and deliver a battery of touchscreen and voice assessments, as well as fully customizable electronic questionnaires and scales. The Company's therapeutic areas include attention deficit hyperactivity disorder (ADHD), Alzheimer's Disease, Autism Spectrum Disorder, Depression, Down's Syndrome, Drug Abuse Liability, Epilepsy, Parkinson's Disease, Stroke and Cerebrovascular Disease, Traumatic Brain Injury, and others.
Back to dashboard
Company Information
About this company
Key people
Nick Rodgers
Non-Executive Chairman of the Board
Robert Roland Baker
Chief Executive Officer, Senior Executive Director
Ronald Openshaw
Chief Financial Officer, Head of Corporate Development, Executive Director
Simon McKeating
Company Secretary
Stuart Gall
Non-Executive Independent Director
Jonathan Kempster
Non-Executive Independent Director
Click to see more
Key facts
- Shares in issue54.04m
- EPICCOG
- ISINGB00B8DV9647
- LocationUnited Kingdom
- SectorTechnology
- IndustrySoftware & Programming
- Market cap£17.54m
- Employees74
- ExchangeLondon Stock Exchange (LON)
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.